Pfizer, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert Bourla
- Full Time Employees
- 75,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 66 Hudson Boulevard East New York NY United States 10001-2192
- IPO Date
- Jan 17, 1944
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs
Diamond Hill Large Cap Fund Q3 2026 Portfolio Update
5 High-Yield Dividend Stocks That Could Hold Up When the Market Falls
Buy, Sell, or Hold? Friday’s Top Upgrades and Downgrades: Becton Dickinson, BJ’s Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More
Pfizer (NYSE:PFE) Hits New 12-Month High on Analyst Upgrade
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Are Your Dividends Safe? 4 Companies Whose Debt Is Competing With the Payout
Pfizer Inc. $PFE Shares Newly Acquired by Associated Banc Corp
Pfizer: The Portfolio Transformation Is Gaining Momentum
Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield
Pfizer: 3 Key Takeaways for Long-Term Investors
Amazon, Pfizer, Eaton And A Financial Stock On CNBC's ‘Final Trades'
Pfizer Q3 Earnings Call Highlights
Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial
Roth IRA vs. Taxable Account: How Much of $11,400 in Dividends Would You Keep?